Women with early breast cancer have varying outcomes with zoledronic acid treatment depending on MAF positivity, according to the AZURE trial.
Extended AI did not improve disease-free survival for all HR-positive breast cancers; however, certain high-risk patients may benefit from therapy beyond 5 years.
A phase II study found that the immunotherapy agent pembrolizumab has meaningful clinical activity in patients with two subtypes of advanced sarcoma.
The combination of selumetinib and docetaxel did not improve progression-free survival among patients with advanced or metastatic non–small-cell lung cancer vs placebo plus docetaxel.
Elderly patients, including those treated with an R-CHOP regimen, tend to have poor outcomes regardless of salvage therapy.
A large cohort study found no concerning safety issues associated with the use of human papillomavirus (HPV) vaccine in adult women. There was an increased rate of celiac disease, but this may be related to general underdiagnosis of the condition and its unmasking at vaccination visits.
The pharmaceutical company AstraZeneca retracted a paper and acknowledged that some preclinical data were falsified regarding its developmental agent acalabrutinib, which is under investigation for use in a number of malignancies.
Extending the platinum-free interval following disease progression in ovarian cancer with a non-platinum agent does not improve outcomes over the standard practice of using a platinum-based chemotherapy, according to a prospective trial.
A new randomized trial found that neoadjuvant trastuzumab/pertuzumab alone yields a substantially worse rate of pathologic complete response compared with paclitaxel plus the two anti-HER2 agents for women with early HER2-positive breast cancer.
Abbreviated chemotherapy is as effective as a full course in patients with chronic lymphocytic leukemia who achieve early minimal residual disease–negative complete responses.